RemeGen seeks shareholder approval for renewed connected transactions, policy updates

RemeGen Co., Ltd. announced a 2025 Third Extraordinary General Meeting (EGM) to consider resolutions for 2026-2028, including renewing several day-to-day related party transactions for three years, effective January 1, 2026. These renewals cover agreements with MabPlex for master services (annual caps of RMB50m to RMB70m), materials purchase with CelluPro (annual caps of RMB40m to RMB85m), and property lease with MabPlex (annual caps of RMB1.8m).

Additional renewals involve a CRC Services Framework Agreement with Kangkang (annual caps of RMB31m to RMB39m) and a General Services Framework Agreement with RC Pharma (annual caps of RMB47m). The EGM will also address the renewal of one-off connected transactions, including equipment leases and property leases with Yeda Incubation and RC Pharma. The equipment lease with Yeda Incubation has an annual rental of RMB4.5m, and a Yeda Incubation building lease involves total annual rentals plus real estate tax of RMB34,917,896.

Shareholders will also vote on amendments to the Management Policies for Related (Connected) Transactions, External Guarantees, External Investment, and Raised Proceeds to comply with regulatory changes from the Shanghai Stock Exchange and HKEX. Controlling shareholders and their associates will abstain from voting on related party transactions due to material interest.